Anhedonia in Depression and Schizophrenia: Brain Reward and Aversion Circuits

Liang, Siming; Wu, Yue; Hanxiaoran, Li; Greenshaw, Andrew J.; Li, Tao

doi:10.2147/ndt.s367839

Cited by 23 publications

(17 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anhedonia is a transdiagnostic symptom for many psychiatric disorders, particularly schizophrenia and depression (Lambert et al, 2018 ; Liang et al, 2022 ). According to DSM‐5 , anhedonia is a core symptom of schizophrenia and depression.…”

Section: Introductionmentioning

confidence: 99%

“…There has been growing interest in developing effective interventions for anhedonia. For schizophrenia patients, atypical antipsychotics appear to be more effective for anhedonia than typical antipsychotics, but a considerable proportion of schizophrenia patients exhibit disabling anhedonia symptoms after medication treatment (Liang et al, 2022 ). For patients with depression, anhedonia can also be resistant to many first‐line antidepressants (Fusar‐Poli et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

“…Although both schizophrenia patients and patients with depression showed anticipatory and consummatory anhedonia, such symptoms apparently constituted a “state” in patients with depression (i.e., anhedonia may fluctuate with the severity of depressive symptoms, illness duration, and relapses); but anticipatory anhedonia appeared to be a “trait” in schizophrenia patients (Li et al, 2015 ). Interestingly, some studies suggested that schizophrenia and depression may share similar neurobiological alterations in the frontostriatal and mesocorticolimbic circuits underlying the reward system (Lambert et al, 2018 ; Liang et al, 2022 ; Zhang et al, 2016 ). Such shared neural dysfunctions may explain anhedonia symptoms found in the two different disorders, and the specific brain circuits involved may be targets for neuromodulations.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effect of noninvasive brain stimulation on anhedonia in patients with schizophrenia and depression: A systematic review and meta‐analysis

Chu,

Li,

Wang

et al. 2023

PsyCh Journal

View full text Add to dashboard Cite

Anhedonia is a transdiagnostic symptom found in patients with schizophrenia and depression. Current pharmacological interventions for anhedonia are unsatisfactory in a considerable proportion of patients. There has been growing interest in applying noninvasive brain stimulation (NIBS) to patients with anhedonia. However, evidence for the efficacy of NIBS for anhedonia remain inconsistent. This study systematically identified all studies that measured anhedonia and applied NIBS in patients with schizophrenia or depression. We conducted a search using the various databases in English (PubMed, EBSCOHost (PsycInfo/PsycArticles), Web of Science) and Chinese (China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform) languages, and reviewed original research articles on NIBS published from January 1989 to July 2023. Our search had identified 15 articles for quantitative synthesis, with three concerning schizophrenia samples, 11 concerning samples with depression, and one concerning both clinical samples. We conducted a meta‐analysis based on the 15 included studies, and the results suggested that NIBS could improve anhedonia symptoms in schizophrenia patients and patients with depression, with a medium‐to‐large effect size. Our findings are preliminary, given the limited number of included studies. Future NIBS research should measure anhedonia as a primary outcome and should recruit transdiagnostic samples.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of noninvasive brain stimulation on anhedonia in patients with schizophrenia and depression: A systematic review and meta‐analysis

Chu,

Li,

Wang

et al. 2023

PsyCh Journal

View full text Add to dashboard Cite

show abstract

“…Bupropion is an NA/DA reuptake inhibitor used to reduce demotivational symptoms and increase responses to anticipation, effort, and reward consumption in patients with MDD. 44 A clinical study identified that depressed patients treated with bupropion had an anhedonia rate of 33%, whereas depressed patients treated with other antidepressants, such as SSRIs, had an anhedonia rate of 46%, suggesting that bupropion is more effective than SSRIs in alleviating symptoms such as anhedonia. 45 The interaction between subeffective doses of SePB and bupropion resulted in an antidepressant-like effect in mice.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

Dopaminergic Modulation and Computational ADMET Insights for the Antidepressant-like Effect of N-(3-(Phenylselanyl)prop-2-yn-1-yl)benzamide

Besckow,

Ledebuhr,

Pires

et al. 2024

ACS Chem. Neurosci.

View full text Add to dashboard Cite

The compound N- (3-(phenylselanyl)prop-2-yn-1yl)benzamide (SePB), which combines a selenium atom and a benzamide nucleus in an organic structure, has demonstrated a fast antidepressant-like effect in mice. This action is influenced by the serotonergic system and represents a promising development in the search for novel antidepressant drugs to treat major depressive disorder (MDD), which often resists conventional treatments. This study aimed to further explore the mechanism underlying the antidepressant-like effect of SePB by investigating the involvement of the dopaminergic and noradrenergic systems in the tail suspension test (TST) in mice and evaluating its pharmacokinetic profile in silico. Preadministration of the dopaminergic antagonists haloperidol (0.05 mg/kg, intraperitoneally (i.p.)), a nonselective antagonist of dopamine (DA) receptors, SCH23390 (0.01 mg/kg, subcutaneously (s.c.)), a D 1 receptor antagonist, and sulpiride (50 mg/kg, i.p.), a D 2/3 receptor antagonist, before SePB (10 mg/kg, intragastrically (i.g.)) prevented the anti-immobility effect of SePB in the TST, demonstrating that these receptors are involved in the antidepressant-like effect of SePB. Administration of the noradrenergic antagonists prazosin (1 mg/kg, i.p.), an α 1 -adrenergic antagonist, yohimbine (1 mg/kg, i.p.), an α 2 -adrenergic antagonist, and propranolol (2 mg/kg, i.p.), a β-adrenergic antagonist, did not block the antidepressant-like effect of SePB on TST, indicating that noradrenergic receptors are not involved in this effect. Additionally, the coadministration of SePB and bupropion (a noradrenaline/dopamine reuptake inhibitor) at subeffective doses (0.1 and 3 mg/kg, respectively) produced antidepressant-like effects. SePB also demonstrated good oral bioavailability and low toxicity in computational absorption, distribution, metabolism, excretion, and toxicity (ADMET) analyses. These findings suggest that SePB has potential as a new antidepressant drug candidate with a particular focus on the dopaminergic system.

show abstract

“…12 In depression, there is a lack of satisfaction for everything that was pleasant before. 13 In schizophrenia, the usually pleasant satisfaction becomes unattainable. 14 Anhedonia is a negative symptom of schizophrenia and a symptom of depression.…”

Section: Anhedoniamentioning

confidence: 99%

The effect of vortioxetine on anhedonia in patients with schizophrenia

Greš,

Šagud,

Dickov

2023

Int J Psychiatry Med

View full text Add to dashboard Cite

Objective Anhedonia is a common symptom of depression, but is also a negative symptom of schizophrenia. The purpose of this study was to examine the effects of vortioxetine on anhedonia in patients with schizophrenia. Methods A total of 120 patients with schizophrenia in remission who met inclusion criteria were randomized 1:1 by the envelope method into intervention and control groups. All participants in both groups were divided into three subgroups based on the antipsychotic therapy (olanzapine or risperidone or aripiprazole) that they were receiving. Vortioxetine was administered to those in the intervention group at a fixed dose of 10 mg per day. The Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), and Chapman Scale for Social and Physical Anhedonia (CSPA) were administered. The study lasted 12 weeks. Participants were assessed twice: At baseline and at the end of the study. Six participants dropped out, with 114 remaining. Findings Vortioxetine treatment had a significant effect on the level of physical anhedonia. The treatment interaction was also statistically significant, but with a relatively small effect (F = 3.17, P < .05; η2 = .061). Vortioxetine treatment had a particularly strong effect on the level of social anhedonia. The interaction between the treatment and the type of antipsychotics was also statistically significant with a small effect (F = 5.04, P < 0. 01; η2 = .091). Conclusion The combination of olanzapine and vortioxetine was found to be the best option to reduce symptoms of social and physical anhedonia in these patients with remitted schizophrenia.

show abstract

Anhedonia in Depression and Schizophrenia: Brain Reward and Aversion Circuits

Cited by 23 publications

References 107 publications

The effect of noninvasive brain stimulation on anhedonia in patients with schizophrenia and depression: A systematic review and meta‐analysis

The effect of noninvasive brain stimulation on anhedonia in patients with schizophrenia and depression: A systematic review and meta‐analysis

Dopaminergic Modulation and Computational ADMET Insights for the Antidepressant-like Effect of N-(3-(Phenylselanyl)prop-2-yn-1-yl)benzamide

The effect of vortioxetine on anhedonia in patients with schizophrenia

Contact Info

Product

Resources

About